OncoTherapy Science, Inc. (TYO:4564)
27.00
+1.00 (3.70%)
Jul 3, 2025, 3:30 PM JST
OncoTherapy Science Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade
|
Cash & Short-Term Investments | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade
|
Cash Growth | 58.06% | -52.82% | -39.16% | -36.67% | -38.49% | Upgrade
|
Accounts Receivable | 98 | 35 | 123 | 399 | 152 | Upgrade
|
Other Receivables | - | 153 | - | - | - | Upgrade
|
Receivables | 98 | 188 | 123 | 399 | 152 | Upgrade
|
Inventory | 78 | 73 | 99 | 231 | 41 | Upgrade
|
Other Current Assets | 96 | 29 | 83 | 134 | 102 | Upgrade
|
Total Current Assets | 1,105 | 817 | 1,422 | 2,600 | 3,194 | Upgrade
|
Property, Plant & Equipment | - | - | - | - | 94 | Upgrade
|
Long-Term Investments | 49 | 49 | 89 | 84 | 74 | Upgrade
|
Other Intangible Assets | - | - | - | - | 4 | Upgrade
|
Other Long-Term Assets | 1 | 1 | - | 1 | 2 | Upgrade
|
Total Assets | 1,155 | 867 | 1,511 | 2,685 | 3,368 | Upgrade
|
Current Income Taxes Payable | 163 | 141 | 318 | 558 | 174 | Upgrade
|
Other Current Liabilities | 164 | 218 | 291 | 46 | 20 | Upgrade
|
Total Current Liabilities | 327 | 359 | 609 | 604 | 194 | Upgrade
|
Long-Term Deferred Tax Liabilities | - | - | - | - | 2 | Upgrade
|
Other Long-Term Liabilities | 100 | 155 | 48 | 102 | 97 | Upgrade
|
Total Liabilities | 427 | 514 | 657 | 706 | 293 | Upgrade
|
Common Stock | 50 | 50 | 789 | 789 | 50 | Upgrade
|
Additional Paid-In Capital | 27,516 | 26,322 | 24,793 | 24,793 | 24,054 | Upgrade
|
Retained Earnings | -26,908 | -26,092 | -24,804 | -23,686 | -21,114 | Upgrade
|
Comprehensive Income & Other | 70 | 73 | 76 | 83 | 85 | Upgrade
|
Total Common Equity | 728 | 353 | 854 | 1,979 | 3,075 | Upgrade
|
Shareholders' Equity | 728 | 353 | 854 | 1,979 | 3,075 | Upgrade
|
Total Liabilities & Equity | 1,155 | 867 | 1,511 | 2,685 | 3,368 | Upgrade
|
Net Cash (Debt) | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade
|
Net Cash Growth | 58.06% | -52.82% | -39.16% | -36.67% | -38.49% | Upgrade
|
Net Cash Per Share | 3.19 | 2.48 | 5.80 | 9.79 | 16.44 | Upgrade
|
Filing Date Shares Outstanding | 271.64 | 239.34 | 206.64 | 192.64 | 176.33 | Upgrade
|
Total Common Shares Outstanding | 271.64 | 217.64 | 192.64 | 192.64 | 176.33 | Upgrade
|
Working Capital | 778 | 458 | 813 | 1,996 | 3,000 | Upgrade
|
Book Value Per Share | 2.68 | 1.62 | 4.43 | 10.27 | 17.44 | Upgrade
|
Tangible Book Value | 728 | 353 | 854 | 1,979 | 3,071 | Upgrade
|
Tangible Book Value Per Share | 2.68 | 1.62 | 4.43 | 10.27 | 17.42 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.